Literature DB >> 7070728

Importance of histologic grading in the prognosis of epithelial ovarian carcinoma.

B Sorbe, B Frankendal, B Veress.   

Abstract

Ovarian epithelial carcinomas still have a poor prognosis. Great efforts are being made to improve treatment modalities; chemotherapy in particular is in a period of dynamic development. A basic requirement for the necessary research is a thorough knowledge of the natural history of ovarian cancer and its prognostic influence. In this report the importance of tumor stage, histologic type, and degree of differentiation is analyzed in an unselected and well-controlled Swedish ovarian cancer series comprising 501 cases. The great prognostic significance of tumor grade for survival is demonstrated and it is proposed that this histopathologic factor, as well as tumor stage and histologic type, should be included in the international classification of primary epithelial tumors of the ovary.

Entities:  

Mesh:

Year:  1982        PMID: 7070728

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  12 in total

1.  Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.

Authors:  S Pontikakis; C Papadaki; M Tzardi; M Trypaki; M Sfakianaki; F Koinis; E Lagoudaki; L Giannikaki; A Kalykaki; E Kontopodis; Z Saridaki; N Malamos; V Georgoulias; J Souglakos
Journal:  Pharmacogenomics J       Date:  2016-10-25       Impact factor: 3.550

Review 2.  Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.

Authors:  Xiaoxiang Chen; Jing Zhang; Zhihong Zhang; Hongxia Li; Wenjun Cheng; Jinsong Liu
Journal:  Hum Pathol       Date:  2013-07-11       Impact factor: 3.466

3.  Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival.

Authors:  M E McMenamin; A J O'Neill; E F Gaffney
Journal:  Mol Pathol       Date:  1997-10

4.  Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).

Authors:  Stefan Kommoss; Dietmar Schmidt; Friedrich Kommoss; Juergen Hedderich; Philipp Harter; Jacobus Pfisterer; Andreas du Bois
Journal:  Virchows Arch       Date:  2009-01-27       Impact factor: 4.064

5.  Tumor angiogenesis in advanced stage ovarian carcinoma.

Authors:  H C Hollingsworth; E C Kohn; S M Steinberg; M L Rothenberg; M J Merino
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

6.  Immunohistochemical characterization of undifferentiated carcinomas of the ovary.

Authors:  Y Kuwashima; T Uehara; K Kishi; K Shiromizu; M Matsuzawa; S Takayama
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.

Authors:  Radoslav Chekerov; Irina Klaman; Menelaos Zafrakas; Dominique Könsgen; Alexander Mustea; Beate Petschke; Werner Lichtenegger; Jalid Sehouli; Edgar Dahl
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

8.  Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features.

Authors:  P C Huettner; D S Weinberg; J M Lage
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

9.  On the histogenesis and morphology of ovarian carcinomas.

Authors:  G Dallenbach-Hellweg
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 10.  Ovarian cancer: pathology, biology, and disease models.

Authors:  Daniel G Rosen; Gong Yang; Guangzhi Liu; Imelda Mercado-Uribe; Bin Chang; Xue Sherry Xiao; Jingfang Zheng; Feng-Xia Xue; Jinsong Liu
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.